Tevard Biosciences Appoints Dr. Elisabeth Gardiner as CSO to Advance tRNA Therapies

Tevard Biosciences, Inc., a leader in tRNA-based therapies for genetic diseases, has announced the appointment of Elisabeth Gardiner, Ph.D., as its new Chief Scientific Officer. Dr. Gardiner, with over 25 years of experience in drug discovery and development, is set to propel Tevard's mission forward with her expertise in translational science. Her role will focus on advancing the company's innovative suppressor tRNA platform, which has shown promise in restoring full-length dystrophin in a Duchenne Muscular Dystrophy (DMD) model, marking a significant step towards curing genetic diseases at their root cause.

Daniel Fischer, Tevard's Co-Founder, President, and CEO, highlighted Dr. Gardiner's unique combination of scientific excellence and leadership as pivotal for the company's next growth phase. Her previous roles, including CSO at Tactile Therapeutics and advisory positions in neuroscience and oncology, underscore her capability to drive Tevard's lead programs towards clinical trials and expand its pipeline. Dr. Gardiner's enthusiasm for Tevard's approach, especially its potential to overcome the limitations of conventional gene therapies, underscores the transformative potential of tRNA-based treatments for rare diseases.

Tevard's recent preclinical data demonstrates the efficacy of its tRNA-based therapy in a DMD model, with sustained protein restoration and no adverse effects. This breakthrough paves the way for treating diseases previously deemed untreatable by traditional gene therapy methods. With ongoing projects in TTN-related dilated cardiomyopathy and Dravet syndrome, Tevard is at the forefront of genetic disease treatment innovation. For more information, visit www.tevard.com.